1. Home
  2. Directory
  3. Idaho
  4. Boise
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1164050084

THOMAS MCKAY STROBEL MD
Prescription History 1164050084
Psychiatry & Neurology - Neurology in Boise, ID

NPI Status: Active since March 27, 2020

Contact Information

125 E IDAHO ST
BOISE, ID
ZIP 83712
Phone: (208) 381-7335
Fax: (208) 381-7227

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for THOMAS MCKAY STROBEL MD, an active Neurology specialist practicing in Boise, ID. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 68 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 26 claims alone.

Medication Index

A
G
L
Z
No matching medications currently found on file.

Aptiom

Generic Formulation: Eslicarbazepine AcetateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 17.0
Days Supply 465
ID State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply1,043
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.6% less volume than the regional standard for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $51,204.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,654.92

State Avg Cost Per Claim

$1,917.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Gabapentin

Generic Formulation: GabapentinSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 29.0
Days Supply 870
ID State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills133.2
Peer Average Days Supply3,909
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.7% less volume than the regional standard for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $289.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.71

State Avg Cost Per Claim

$22.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 26
30-Day Fills 43.9
Days Supply 1,317
ID State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills62.7
Peer Average Days Supply1,829
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $889.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.20

State Avg Cost Per Claim

$41.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.0
Days Supply 990
ID State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills93.6
Peer Average Days Supply2,765
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.1% less volume than the regional standard for practitioners inside ID. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,014.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$59.67

State Avg Cost Per Claim

$43.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like THOMAS MCKAY STROBEL MD provides transparency into local medical care patterns within Boise, ID.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.